BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 22807497)

  • 1. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
    Kvols LK; Oberg KE; O'Dorisio TM; Mohideen P; de Herder WW; Arnold R; Hu K; Zhang Y; Hughes G; Anthony L; Wiedenmann B
    Endocr Relat Cancer; 2012 Oct; 19(5):657-66. PubMed ID: 22807497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.
    Wolin EM; Hu K; Hughes G; Bouillaud E; Giannone V; Resendiz KH
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):387-95. PubMed ID: 23765178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
    Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors.
    Chan JA; Ryan DP; Zhu AX; Abrams TA; Wolpin BM; Malinowski P; Regan EM; Fuchs CS; Kulke MH
    Endocr Relat Cancer; 2012 Oct; 19(5):615-23. PubMed ID: 22736724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
    Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
    Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
    Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
    J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
    Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
    Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
    BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.
    Golor G; Hu K; Ruffin M; Buchelt A; Bouillaud E; Wang Y; Maldonado M
    Drug Des Devel Ther; 2012; 6():71-9. PubMed ID: 22573933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
    Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
    Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.
    Petersenn S; Bollerslev J; Arafat AM; Schopohl J; Serri O; Katznelson L; Lasher J; Hughes G; Hu K; Shen G; Reséndiz KH; Giannone V; Beckers A
    J Clin Pharmacol; 2014 Nov; 54(11):1308-17. PubMed ID: 24800725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.
    Broder MS; Beenhouwer D; Strosberg JR; Neary MP; Cherepanov D
    World J Gastroenterol; 2015 Feb; 21(6):1945-55. PubMed ID: 25684964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.
    Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH
    Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease.
    Ben-Shlomo A; Melmed S
    IDrugs; 2007 Dec; 10(12):885-95. PubMed ID: 18041687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pasireotide (SOM230): development, mechanism of action and potential applications.
    Schmid HA
    Mol Cell Endocrinol; 2008 May; 286(1-2):69-74. PubMed ID: 17977644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.
    Dietrich H; Hu K; Ruffin M; Song D; Bouillaud E; Wang Y; Hasskarl J
    Eur J Endocrinol; 2012 May; 166(5):821-8. PubMed ID: 22383336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
    O'Toole D; Ducreux M; Bommelaer G; Wemeau JL; Bouché O; Catus F; Blumberg J; Ruszniewski P
    Cancer; 2000 Feb; 88(4):770-6. PubMed ID: 10679645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.
    Chen X; Shen G; Jiang J; Liu H; Hu K; Darstein C; Lasher J; Hu P
    Clin Ther; 2014 Aug; 36(8):1196-210. PubMed ID: 25012727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.